In addition, a 24-week randomized placebo-controlled study showed that the proinsulin/C-peptide ratio in individuals with T2D was significantly reduced by the administration of canagliflozin as an add-on therapy to teneligliptin [85]. The gene discussed is INS; the disease is type 2 diabetes mellitus.